Table 3.

Tissue Ki67 expression and circulating biomarker levels after 4 wk of preoperative tamoxifen treatment

BiomarkerGroupnMedian (q1-q3)Median change*P
Ki67 (%)Nontreated2822 (20-41)N.a.SRC-1 = 0.08
1 mg tam2613 (10-23)−3SRC-2/TIF-2 = 0.20
5 mg tam1913 (8-25)−2SRC-3/AIB1 = 0.31
20 mg tam1912 (8-18)−8HER-2/neu = 0.77
IGF-I (nmol/L)Nontreated1199 (77-101)−7.4SRC-1 = 0.30
1 mg tam26101 (82-127)−4.1SRC-2/TIF-2 = 0.19
5 mg tam1982 (64-108)−22.4SRC-3/AIB1 = 0.23
20 mg tam1870 (57-92)−36.8HER-2/neu = 0.44
SHBG (nmol/L)Nontreated1541 (36-60)−10.7SRC-1 = 0.53
1 mg tam2652 (40-82)1.5SRC-2/TIF-2 = 0.35
5 mg tam1973 (56-90)8.2SRC-3/AIB1 = 0.16
20 mg tam1877 (68-105)16.5HER-2/neu = 0.28

Abbreviation: N.a., not available.

  • *Median change from baseline levels.

  • P values from ANOVA random effects models investigating potential association between mRNA levels of coactivators or HER-2/neu and biomarker levels after 4 wk of preoperative tamoxifen treatment, adjusting for type of tissue and treatment arms.

  • Histologic information on the nontreated group was collected at the time of surgery and median change of Ki67 could not be calculated.